Grant: Discovery Grants Program - Individual
Simon Fraser University
$47,050.00
Proof of concept molecules and molecular probes in drug discovery
EF 2012-13
Résumé
This proposal describes several of the projects planned or ongoing in our labs on design of chemical probes and optimized proof of concept (PoC) molecules for disease target discovery, validation and drug discovery. An associated project to develop new methods for enantioselective synthesis to facilitate lead optimization is also presented. 1) Leukotrienes (LTs) are implicated in a number of diseases and more recently are postulated to play an important role in inflammatory components of cardiovascular diseases. Inhibitors of LT biosynthesis have been associated with adverse effects which limit their use. A new class of ""anomalous"" inhibitors of leukotriene biosynthesis has recently been discovered whose mechanism of action is not understood. Optimized compounds in this class may exhibit a better chronic safety and tolerability profile. We plan to make affinity probes to identify the molecular target(s) on these compounds in the cell. Identification will allow a better understanding of the fundamental details of mechanism and controls of LT biosynthesis and the potential of inhibitors in this new class as new therapies. This research will also provide the assay tools necessary to optimize such inhibitors to identify viable development compounds. 2) As many compounds in the class of LT inhibitors have activity associated with a single enantiomer at a quaternary aryl chiral center, we plan to develop new and versatile methods for direct synthesis of such molecules based on ortho-directed metalation mediated by novel chiral silyldiamines and aminosiloxanes. Such methods will have broad applicability in organic synthesis. 3) Serine-threonine kinases form a large and highly homologous class of enzymes involved in many cellular processes and implicated in a wide variety of diseases. Selectivity has been an important problem in the development of such inhibitors. We plan to develop tools to assess kinase expression (in normal and diseased tissue) and selectivity of inhibition in cells. These tools will be based on affinity probes derived from the pan-selective kinase inhibitor staurosporine and analogs. Such tools will provide kinase expression maps and enzyme occupancy assays to enable drug discovery and optimization.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
341724-2008
Name nom
Young, Robert
Department département
Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2008
Award amount
47050
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
5
Nb partie
5
Application title
Proof of concept molecules and molecular probes in drug discovery
Keyword
NSERC
Application summary
This proposal describes several of the projects planned or ongoing in our labs on design of chemical probes and optimized proof of concept (PoC) molecules for disease target discovery, validation and drug discovery. An associated project to develop new methods for enantioselective synthesis to facilitate lead optimization is also presented. 1) Leukotrienes (LTs) are implicated in a number of diseases and more recently are postulated to play an important role in inflammatory components of cardiovascular diseases. Inhibitors of LT biosynthesis have been associated with adverse effects which limit their use. A new class of ""anomalous"" inhibitors of leukotriene biosynthesis has recently been discovered whose mechanism of action is not understood. Optimized compounds in this class may exhibit a better chronic safety and tolerability profile. We plan to make affinity probes to identify the molecular target(s) on these compounds in the cell. Identification will allow a better understanding of the fundamental details of mechanism and controls of LT biosynthesis and the potential of inhibitors in this new class as new therapies. This research will also provide the assay tools necessary to optimize such inhibitors to identify viable development compounds. 2) As many compounds in the class of LT inhibitors have activity associated with a single enantiomer at a quaternary aryl chiral center, we plan to develop new and versatile methods for direct synthesis of such molecules based on ortho-directed metalation mediated by novel chiral silyldiamines and aminosiloxanes. Such methods will have broad applicability in organic synthesis. 3) Serine-threonine kinases form a large and highly homologous class of enzymes involved in many cellular processes and implicated in a wide variety of diseases. Selectivity has been an important problem in the development of such inhibitors. We plan to develop tools to assess kinase expression (in normal and diseased tissue) and selectivity of inhibition in cells. These tools will be based on affinity probes derived from the pan-selective kinase inhibitor staurosporine and analogs. Such tools will provide kinase expression maps and enzyme occupancy assays to enable drug discovery and optimization.